Patent intelligence · US
US 6921765
1-Azabicyclo[2.2.2]octan-3-one derivatives and maleimide derivatives and their use for treating cancer tumors
1-Azabicyclo[2.2.2]octan-3-one derivatives and maleimide derivatives and their use for treating cancer tumors
Patent details — US 6921765
- Jurisdiction
- US
- Status
- expired
- Grant date
- Jul 26, 2005
- Expiration
- Jul 21, 2025
- Applicant
- APREA AB
- Claims
- 2
- CPC classes
- A61P, A61P35/00
Quick answer
US 6921765 (1-Azabicyclo[2.2.2]octan-3-one derivatives and maleimide derivatives and their use for treating cancer tumors) is held by APREA AB. Status: expired. Granted Jul 26, 2005. Expires Jul 21, 2025 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- APREA AB
- Grant date
- Expiration
- Claims
- 2
- CPC classes
- A61P, A61P35/00
More from APREA AB
Related pharmaceutical patents in our USPTO index.
-
US 9061016
Aqueous solution comprising 3-quinuclidinones for the treatment hyperproliferative, autoimmune and heart disease
granted -
US 7902167
Compounds and methods for down-regulating Wrap53 protein by RNA interference
granted -
US 7759361
Azabicyclooctan-3-one derivatives and use thereof
granted -
US 7659278
Use of low molecular weight compounds for preparing a medicament useful in treating mutant p53 mediated diseases
granted -
US 7348330
1-azabicyclo [2,2,2] octan-3-one derivatives
granted
Frequently asked questions
What is US patent 6921765?
US 6921765 (1-Azabicyclo[2.2.2]octan-3-one derivatives and maleimide derivatives and their use for treating cancer tumors) is held by APREA AB. Status: expired. Granted Jul 26, 2005. Expires Jul 21, 2025 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6921765?
APREA AB is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 6 pharmaceutical patents for this assignee.
When does US 6921765 expire?
Our index shows an expiration date of Jul 21, 2025 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.